drug_type
RELEVANT_DRUG
intervention_type
Antibody-drug conjugate (ADC)
drug_description
An antibody-drug conjugate carrying a topoisomerase I inhibitor payload; binds a tumor cell-surface antigen, is internalized, and releases the payload to induce DNA damage and tumor cell death.
nci_thesaurus_concept_id
C200198
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) nectin-4 (PVRL4) conjugated, via a cleavable linker, to a topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-nectin-4 ADC SHR-A2102 targets and binds to nectin-4 expressed on tumor cells. Upon binding, internalization and linker cleavage, topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing nectin-4. Nectin-4 is overexpressed in a variety of cancers, but has a restricted distribution in normal tissue.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
An anti-nectin-4 IgG1 antibody-drug conjugate that binds nectin-4 on tumor cells, is internalized, and via a cleavable linker releases a topoisomerase I inhibitor payload. The payload inhibits topoisomerase I, disrupting DNA replication and causing DNA damage, cell-cycle arrest, and apoptosis in nectin-4–expressing cancer cells.
drug_name
SHR-A2102
nct_id_drug_ref
NCT06639347